Immunome (NASDAQ:IMNM) Insider Kinney Horn Sells 90,616 Shares

Immunome, Inc. (NASDAQ:IMNM) insider Kinney Horn sold 90,616 shares of Immunome stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the completion of the sale, the insider owned 50,366 shares of the company’s stock, valued at $1,263,682.94. This represents a 64.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kinney Horn also recently made the following trade(s):

• On Tuesday, July 7th, Kinney Horn sold 1,092 shares of Immunome stock. The shares were sold at an average price of $25.00, for a total transaction of $27,300.00.

Immunome Trading Up 1.2%

Shares of IMNM stock opened at $25.82 on Friday. Immunome, Inc. has a 12-month low of $8.66 and a 12-month high of $27.65. The stock has a market capitalization of $2.92 billion, a P/E ratio of -10.85 and a beta of 2.08. The firm’s 50 day moving average is $21.43 and its 200 day moving average is $22.14.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Nan Fung Trinity HK Ltd. raised its holdings in Immunome by 20.7% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock valued at $15,349,000 after acquiring an additional 122,450 shares during the period. Vanguard Group Inc. lifted its position in shares of Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after acquiring an additional 1,144,788 shares in the last quarter. Profund Advisors LLC lifted its position in shares of Immunome by 121.7% in the fourth quarter. Profund Advisors LLC now owns 42,700 shares of the company’s stock valued at $917,000 after acquiring an additional 23,440 shares in the last quarter. Maven Securities LTD bought a new position in shares of Immunome in the fourth quarter worth about $1,611,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Immunome in the fourth quarter worth about $3,652,000. Institutional investors own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IMNM. Wedbush reissued an “outperform” rating and issued a $31.00 target price on shares of Immunome in a report on Tuesday, July 21st. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Leerink Partners reduced their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. HC Wainwright reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.18.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.